Literature DB >> 1347701

Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis.

S Ogata1, Y Misumi, E Tsuji, N Takami, K Oda, Y Ikehara.   

Abstract

The active site of dipeptidyl peptidase IV (DPPIV) was examined by chemical modification and site-directed mutagenesis. Purified DPPIV was covalently modified with [3H]diisopropyl fluorophosphate (DFP). The radiolabeled DPPIV was digested with lysyl endopeptidase, and the peptides were separated by high-performance liquid chromatography. A single 3H-containing peptide was obtained and analyzed for amino acid sequence and radioactivity distribution. A comparison of the determined sequence with the predicted primary structure of DPPIV [Ogata, S., Misumi, Y., & Ikehara, Y. (1989) J. Biol. Chem. 264, 3596-3601] revealed that [3H]DFP was bound to Ser631 within the sequence Gly629-Trp-Ser-Tyr-Gly633, which corresponds to the consensus sequence Gly-X-Ser-X-Gly proposed for serine proteases. To further identify the essential residues in the active-site sequence, we modified the DPPIV cDNA by site-directed mutagenesis to encode its variants. Expression of the mutagenized cDNAs in COS-1 cells demonstrated that any single substitution of Gly629, Ser631, or Gly633 with other residues resulted in the complete loss of the enzyme activity and DFP binding. Although substitution of Trp630----Glu or Tyr632----Phe caused no effect on the enzyme activity, that of Tyr632----Leu or Gly abolished the activity. These results indicate that the sequence Gly-X-Ser-(Tyr)-Gly is essential for the expression of the DPPIV activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347701     DOI: 10.1021/bi00124a019

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment.

Authors:  Raghuvir R S Pissurlenkar; Mushtaque S Shaikh; Evans C Coutinho
Journal:  J Mol Model       Date:  2007-08-04       Impact factor: 1.810

2.  Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.

Authors:  Cui Li; Weiqiang Lu; Chunhua Lu; Wen Xiao; Xu Shen; Jin Huang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-30       Impact factor: 1.810

3.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.

Authors:  T Tanaka; J Kameoka; A Yaron; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

4.  Dipeptidyl aminopeptidase IV from Stenotrophomonas maltophilia exhibits activity against a substrate containing a 4-hydroxyproline residue.

Authors:  Yoshitaka Nakajima; Kiyoshi Ito; Tsubasa Toshima; Takashi Egawa; Heng Zheng; Hiroshi Oyama; Yu-Fan Wu; Eiji Takahashi; Kiyoshi Kyono; Tadashi Yoshimoto
Journal:  J Bacteriol       Date:  2008-09-26       Impact factor: 3.490

5.  Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene.

Authors:  C A Abbott; E Baker; G R Sutherland; G W McCaughan
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.

Authors:  Kathleen Aertgeerts; Sheng Ye; Mike G Tennant; Michelle L Kraus; Joe Rogers; Bi-Ching Sang; Robert J Skene; David R Webb; G Sridhar Prasad
Journal:  Protein Sci       Date:  2004-01-10       Impact factor: 6.725

7.  Substrate selectivity of bacterial monoacylglycerol lipase based on crystal structure.

Authors:  Toshiharu Tsurumura; Hideaki Tsuge
Journal:  J Struct Funct Genomics       Date:  2014-06-04

8.  Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV.

Authors:  T Tanaka; J S Duke-Cohan; J Kameoka; A Yaron; I Lee; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Exploring the antidiabetic potential of compounds isolated from Anacardium occidentale using computational aproach: ligand-based virtual screening.

Authors:  Victor Okoliko Ukwenya; Sunday Aderemi Adelakun; Olusola Olalekan Elekofehinti
Journal:  In Silico Pharmacol       Date:  2021-04-03

10.  Retention of p63 in an ER-Golgi intermediate compartment depends on the presence of all three of its domains and on its ability to form oligomers.

Authors:  A Schweizer; J Rohrer; H P Hauri; S Kornfeld
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.